Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and markets VOQUEZNA, a potassium-competitive acid blocker (PCAB) designed to treat gastrointestinal conditions including erosive and non-erosive gastroesophageal reflux disease (GERD) and Helicobacter pylori infection. The company generates revenue by selling three VOQUEZNA formulations—VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK—to pharmaceutical distributors and pharmacies in the United States, leveraging a sales force of approximately 300 representatives focused on gastroenterologists and high-prescribing providers. Vonoprazan offers clinical advantages over traditional proton pump inhibitors through rapid onset, potent acid suppression, and sustained 24-hour control without requiring acid-mediated activation, positioning it to address unmet needs among the tens of millions of U.S. adults with GERD, particularly those experiencing inadequate symptom relief from existing PPI therapies.